Mounjaro Explained: Diabetes Indication and Dosing

Educational, not medical advice

This content is for general information only. It is not medical advice, a diagnosis, or a treatment plan. Beema Health's live clinical offering is telehealth medical weight-loss. Beema Health serves patients located in the United States only. It is not an international service. Licensed providers can evaluate adults in all 50 US states through telehealth. A licensed clinician reviews each intake and decides whether any medication is appropriate. Completing an online intake does not guarantee a prescription. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. They are not the same as FDA-approved branded products. This library does not promise weight-loss results, show before-and-after photos, or collect health information.

What Mounjaro is

Mounjaro is Eli Lilly's tirzepatide injection approved to improve blood sugar in type 2 diabetes, used with diet and exercise. Tirzepatide is a dual GIP and GLP-1 receptor agonist given once weekly. The FDA first approved Mounjaro in 2022 for adults. Confirm the current label for any pediatric expansion (some updates include patients 10 years and older). This article focuses on the adult diabetes indication that most searchers mean.

Public conversation often treats Mounjaro as a weight-loss brand. The labeled indication is glycemic control in type 2 diabetes. A separately branded tirzepatide product, Zepbound, carries chronic weight-management and OSA indications. Mixing up the two names can confuse pharmacies, insurers, and patients. This article stays with Mounjaro's diabetes label.

Educational only - not medical advice, not an offer to sell Mounjaro. Beema Health does not dispense this brand. Prescription required. Prescribing is never guaranteed after an online questionnaire. Individual results vary.

How tirzepatide helps type 2 diabetes

GIP and GLP-1 are incretin hormones. Activating their receptors can increase glucose-dependent insulin secretion, decrease glucagon, slow gastric emptying, and reduce calorie intake. In type 2 diabetes, the clinical goal on the Mounjaro label is A1C reduction, not a cosmetic weight target.

The SURPASS program compared tirzepatide with placebo or active diabetes medicines. SURPASS-2, published in the New England Journal of Medicine, compared tirzepatide with semaglutide 1 mg weekly (an Ozempic-range diabetes dose, not Wegovy 2.4 mg) in adults with type 2 diabetes on metformin. Mean A1C and weight reductions were larger with tirzepatide in that study. Gastrointestinal adverse events were common with both medicines.

Labeled Mounjaro dosing

Start at 2.5 mg subcutaneously once weekly for four weeks. Increase to 5 mg weekly. If additional glycemic control is needed, increase by 2.5 mg after at least four weeks on the current dose. Available strengths typically include 2.5, 5, 7.5, 10, 12.5, and 15 mg. The maximum recommended dosage is 15 mg once weekly.

The 2.5 mg dose is for treatment initiation and is not intended as a maintenance dose for glucose control. If a dose is missed, follow the current Instructions for Use (commonly: take it within four days; if more time has passed, skip and resume the regular day). Confirm missed-dose rules on the latest label.

When Mounjaro is added to insulin or a sulfonylurea, those doses may need to be lowered to reduce hypoglycemia. Only the prescriber should make that change. Never share pens.

Weeks 1-4: 2.5 mg once weekly
Then 5 mg once weekly
Optional further steps every 4+ weeks: 7.5, 10, 12.5, then 15 mg maximum

Who was studied and who should not use it

Trials enrolled adults with type 2 diabetes. Mounjaro is not indicated for type 1 diabetes. It is contraindicated with personal or family history of MTC or with MEN 2, and after serious hypersensitivity to tirzepatide.

Use caution and clinician judgment with a history of pancreatitis, severe gastrointestinal disease including severe gastroparesis (not recommended), diabetic retinopathy monitoring if glucose drops quickly, kidney impairment during dehydrating GI illness, and pregnancy. Discuss surgery and anesthesia because delayed gastric emptying can raise aspiration risk.

Safety profile in brief

The boxed warning matches other incretin injectables in this class: rodent thyroid C-cell tumors; unknown human risk; contraindication in MTC and MEN 2. The most common adverse reactions in diabetes trials included nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

Serious risks include pancreatitis, hypoglycemia with insulin or insulin secretagogues, hypersensitivity, acute gallbladder disease, and acute kidney injury associated with gastrointestinal fluid loss. Severe gastrointestinal reactions are described in current labels for tirzepatide products. Seek emergency care for severe persistent abdominal pain, swelling of the face or throat, or signs of severe hypoglycemia.

Weight change, switching, and stopping

Weight reduction in SURPASS was a secondary finding in people being treated for type 2 diabetes. It does not convert Mounjaro into a weight-management indication. If a person's primary goal is labeled chronic weight management with tirzepatide, that conversation is about Zepbound's label, eligibility, and access - still a clinician decision, and not a Beema product.

Switching from Mounjaro to another GLP-1 or dual agonist, or stopping entirely, needs a plan for glucose monitoring. See switching GLP-1 medications and stopping Mounjaro. Beema Health does not offer Mounjaro. People exploring medical weight loss through telehealth can read Beema's program overview; that is not a claim that Beema will continue a Mounjaro prescription.

Frequently asked questions

Is Mounjaro approved for weight loss?

No. Mounjaro is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Weight change was observed in diabetes trials, but chronic weight management is the labeled role of Zepbound, a different tirzepatide product. A clinician should not be asked to treat a webpage as a prescribing guideline.

How do you take Mounjaro?

Mounjaro is injected subcutaneously once weekly in the abdomen, thigh, or upper arm, with or without meals. The recommended starting dose is 2.5 mg weekly for four weeks, then 5 mg. Further 2.5 mg increases may occur after at least four weeks on the current dose, up to a maximum of 15 mg weekly, based on glycemic response and tolerability.

Does Beema Health prescribe Mounjaro?

No. Beema Health does not sell or dispense branded Mounjaro. This article is educational. If a Beema clinician prescribes tirzepatide, it is compounded tirzepatide when legally available and clinically appropriate, not Mounjaro. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. See the compounded tirzepatide page. Completing intake does not guarantee a prescription.

What were the SURPASS-2 findings?

SURPASS-2 compared once-weekly tirzepatide with once-weekly semaglutide 1 mg in adults with type 2 diabetes. Tirzepatide produced larger reductions in A1C and body weight on average than semaglutide 1 mg in that diabetes trial. That comparison is not the same as a Zepbound-versus-Wegovy obesity trial, and it does not tell an individual which branded product they will be prescribed.

Who should not use Mounjaro?

Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN 2, and in people with a serious hypersensitivity to tirzepatide. It is not for type 1 diabetes or for treating diabetic ketoacidosis. Additional warnings include pancreatitis, gallbladder disease, hypoglycemia with insulin or sulfonylureas, acute kidney injury from dehydration, severe gastrointestinal disease, and aspiration risk with anesthesia.

What happens if I stop Mounjaro?

Glucose control often worsens when a diabetes medicine is stopped, and body weight may rise. Stopping should be planned with the diabetes clinician, especially if insulin or other agents are on board. See the articles on stopping Mounjaro and stopping tirzepatide for trial context. Do not stop suddenly without a monitoring plan.

Sources

Related education

Program pages

These pages describe Beema's live medical weight-loss offering. They are commercial pages, not this educational article.

Beema's live offering is medical weight-loss care

Licensed providers can evaluate adults in all 50 US states through telehealth. Beema Health serves patients located in the United States only. It is not an international service. A licensed clinician reviews each intake and decides whether any medication is appropriate. Completing an online intake does not guarantee a prescription. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate.

Beema Health is a LegitScript-certified website. Certification means the certified site is monitored against LegitScript's healthcare merchant standards. It is not an endorsement of Beema's products, not a statement that compounded medication is safe or FDA-approved, and not a claim about competitors. Beema Health has obtained Google's healthcare certification for prescription-drug advertising in the United States. That certification is about advertising eligibility. It is not a Google endorsement of Beema, of any medication, or of any clinical outcome.

Get Started

What is Mounjaro?